Mizuho Maintains Outperform on Spyre Therapeutics, Raises Price Target to $120

Benzinga Newsdesk www.benzinga.com Positive 93.3%

Neg 0% Neu 0% Pos 93.3%

Mizuho analyst Joseph Catanzaro maintains Spyre Therapeutics (NASDAQ:SYRE) with a Outperform and raises the price target from $84 to $120.